MX367127B - Formulación de fármaco de liberación retardada que comprende un núcleo y un recubrimiento para el núcleo que comprende al menos dos o tres capas poliméricas. - Google Patents

Formulación de fármaco de liberación retardada que comprende un núcleo y un recubrimiento para el núcleo que comprende al menos dos o tres capas poliméricas.

Info

Publication number
MX367127B
MX367127B MX2018010475A MX2018010475A MX367127B MX 367127 B MX367127 B MX 367127B MX 2018010475 A MX2018010475 A MX 2018010475A MX 2018010475 A MX2018010475 A MX 2018010475A MX 367127 B MX367127 B MX 367127B
Authority
MX
Mexico
Prior art keywords
polymeric material
drug
core
layer
inner layer
Prior art date
Application number
MX2018010475A
Other languages
English (en)
Inventor
Carlos Bravo González Roberto
Buser Thomas
Jean-Claude Goutte Frédéric
Waseh Basit Abdul
Cristina Freire Ana
José Oliveira Varum Felipe
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46025554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367127(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of MX367127B publication Critical patent/MX367127B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Laminated Bodies (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Grain Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La liberación retardada de un fármaco al colon se logra de una formulación de liberación retardada que comprende un núcleo y un recubrimiento para el núcleo. El núcleo comprende un fármaco y un recubrimiento que comprende una capa interior y al menos una capa entre el núcleo y la capa exterior seleccionada del grupo que consiste de una capa de aislamiento y una capa interior. La capa exterior comprende una mezcla de un primer material polimérico que es susceptible a ataques por parte de la bacteria colónica, y un segundo material polimérico que tiene un umbral de pH a aproximadamente pH 5 o más alto. La capa interior comprende un tercer material polimérico que es soluble en el fluido intestinal o en el fluido gastrointestinal, tal tercer material polimérico se selecciona de ácido policarboxílico al menos parcialmente neutralizado y un polímero no iónico. En modalidades en donde el tercer material polimérico es un polímero no iónico, la capa interior comprende al menos un agente regulador del pH y una base. La capa de aislamiento comprende un polímero no iónico que es soluble en el fluido intestinal o fluido gastrointestinal. El exterior es un medio acuoso con un segundo material polimérico en un medio orgánico. Las ventajas de las formulaciones de acuerdo con la presente invención incluyen la liberación acelerada del fármaco cuando se expone a condiciones colónicas y la reducción o eliminación del efecto de los alimentos y/o alcohol en la liberación del fármaco después de la administración.
MX2018010475A 2012-04-30 2013-04-29 Formulación de fármaco de liberación retardada que comprende un núcleo y un recubrimiento para el núcleo que comprende al menos dos o tres capas poliméricas. MX367127B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261640217P 2012-04-30 2012-04-30
EP12166110.2A EP2659881B1 (en) 2012-04-30 2012-04-30 A delayed release drug formulation
PCT/EP2013/058923 WO2013164316A1 (en) 2012-04-30 2013-04-29 A delayed release drug formulation

Publications (1)

Publication Number Publication Date
MX367127B true MX367127B (es) 2019-08-06

Family

ID=46025554

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2014012887A MX362529B (es) 2012-04-30 2013-04-29 Formulación de fármaco de liberación retardada que comprende un núcleo y un recubrimiento multicapa para el núcleo que comprende al menos tres capas poliméricas.
MX2018010475A MX367127B (es) 2012-04-30 2013-04-29 Formulación de fármaco de liberación retardada que comprende un núcleo y un recubrimiento para el núcleo que comprende al menos dos o tres capas poliméricas.
MX2014012888A MX366677B (es) 2012-04-30 2013-04-29 Formulación de fármaco de liberación retardada que comprende un núcleo y un recubrimiento para el núcleo que comprende al menos dos o tres capas poliméricas.
MX2018010476A MX373249B (es) 2012-04-30 2013-04-29 Formulacion de farmaco de liberacion retardada que comprende un nucleo y un recubrimiento multicapa para el nucleo que comprende al menos tres capas polimericas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014012887A MX362529B (es) 2012-04-30 2013-04-29 Formulación de fármaco de liberación retardada que comprende un núcleo y un recubrimiento multicapa para el núcleo que comprende al menos tres capas poliméricas.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2014012888A MX366677B (es) 2012-04-30 2013-04-29 Formulación de fármaco de liberación retardada que comprende un núcleo y un recubrimiento para el núcleo que comprende al menos dos o tres capas poliméricas.
MX2018010476A MX373249B (es) 2012-04-30 2013-04-29 Formulacion de farmaco de liberacion retardada que comprende un nucleo y un recubrimiento multicapa para el nucleo que comprende al menos tres capas polimericas.

Country Status (41)

Country Link
US (6) US10226430B2 (es)
EP (6) EP3187171B1 (es)
JP (2) JP6621662B2 (es)
KR (6) KR102102198B1 (es)
CN (5) CN110237056B (es)
AR (1) AR090898A1 (es)
AU (4) AU2013255914B2 (es)
BR (3) BR112014026933B1 (es)
CA (4) CA2871017A1 (es)
CL (2) CL2014002795A1 (es)
CO (2) CO7141433A2 (es)
CR (4) CR20190246A (es)
CU (1) CU24304B1 (es)
CY (4) CY1120215T1 (es)
DK (5) DK2659881T3 (es)
EA (2) EA032514B1 (es)
ES (6) ES2655622T3 (es)
GE (4) GEP201706758B (es)
HR (2) HRP20180068T1 (es)
HU (5) HUE036187T2 (es)
JO (6) JOP20200144A1 (es)
LT (5) LT2659881T (es)
ME (2) ME03364B (es)
MX (4) MX362529B (es)
MY (3) MY169161A (es)
NO (1) NO2659881T3 (es)
NZ (3) NZ629262A (es)
PE (3) PE20150129A1 (es)
PH (2) PH12014502339B1 (es)
PL (5) PL2659881T3 (es)
PT (5) PT2659881T (es)
RS (5) RS56839B1 (es)
SA (2) SA113340508B1 (es)
SG (2) SG11201406798WA (es)
SI (5) SI2659881T1 (es)
SM (5) SMT201800095T1 (es)
TN (2) TN2014000441A1 (es)
TR (3) TR201809416T4 (es)
TW (3) TWI705833B (es)
UY (1) UY34772A (es)
WO (2) WO2013164316A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2655622T3 (es) 2012-04-30 2018-02-20 Tillotts Pharma Ag Una formulación de fármaco de liberación retardada
HRP20192210T1 (hr) * 2012-04-30 2020-02-21 Tillotts Pharma Ag Formulacija lijeka s produženim otpuštanjem
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
CA2901166C (en) * 2013-02-22 2020-03-24 Zeria Pharmaceutical Co., Ltd. Enteric coated tablet
NZ717159A (en) 2013-10-29 2019-06-28 Tillotts Pharma Ag A delayed release drug formulation
EA030615B1 (ru) 2013-12-24 2018-08-31 Сентисс Фарма Прайвет Лимитед Офтальмологический раствор бримонидина для местного применения
MX391477B (es) 2015-06-01 2025-03-19 Xeno Biosciences Inc Metodos y composiciones para modular la microbiota intestinal y para manejar el peso
EP4119539A1 (en) 2015-09-23 2023-01-18 XWPharma Ltd. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
CN105816883B (zh) * 2016-02-03 2018-12-14 华南师范大学 一种负载抗癌药物姜黄素的益生菌叶酸靶向载体及其制备方法
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
CA3045011A1 (en) * 2016-11-30 2018-06-07 Xeno Biosciences Inc. Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota
ES3032290T3 (en) 2018-03-20 2025-07-16 Theriva Biologics Inc Intestinal alkaline phosphatase formulations
MX2020009900A (es) * 2018-03-23 2021-01-08 Palatin Technologies Inc Formulaciones peptidicas especificas para el receptor de melanocortinas y metodos para un suministro especifico en el tubo gastrointestinal.
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
EP3662898A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
ES3002632T3 (en) 2018-12-07 2025-03-07 Tillotts Pharma Ag Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
ES2994844T3 (en) * 2018-12-07 2025-02-03 Tillotts Pharma Ag Colonic drug delivery formulation
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
HUE057346T2 (hu) * 2018-12-10 2022-05-28 Aphaia Ip Ag Orális gyógyászati adagolási forma metabolikus rendellenességek és rokon betegségek enterokinek megtervezett felszabadításával történõ kezelésére
CN111617047B (zh) * 2019-02-27 2021-06-22 广州喜鹊医药有限公司 一种含tbn或其盐或其水合物的药物组合物及其制备方法
GB201905940D0 (en) * 2019-04-29 2019-06-12 Intract Pharma Ltd 5-aminolevulinic acid for the local treatment of inflammatory bowel disease
WO2020257017A1 (en) 2019-06-18 2020-12-24 Progenity, Inc. Ingestible device with component capable of residing in the gastrointestinal tract
MX2022001865A (es) 2019-08-12 2022-03-11 Massachusetts Inst Technology Articulos y metodos para la administracion de agentes terapeuticos.
FR3102931B1 (fr) * 2019-11-13 2021-12-24 Ethypharm Sa Procédé de fabrication d’une composition pharmaceutique à administration orale et à délivrance colonique
EP4057998A1 (fr) * 2019-11-13 2022-09-21 Ethypharm Procédé de fabrication d'une composition pharmaceutique à administration orale et à délivrance colonique
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN111567678A (zh) * 2020-05-11 2020-08-25 四川英格瑞生物科技有限公司 无抗畜类肠道保健剂及其制备方法
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent
US20230263735A1 (en) * 2020-07-13 2023-08-24 Kirin Holdings Kabushiki Kaisha Film coated tablet
WO2022254456A1 (en) * 2021-06-01 2022-12-08 Nbi Biosciences Pvt Ltd Microbial-triggered oral intestinal drug delivery formulation and method of preparation thereof
CN117024341A (zh) * 2022-04-30 2023-11-10 宁波大学 一类d-2a不对称型热活化延迟荧光材料的合成及其应用
TW202535385A (zh) * 2023-10-16 2025-09-16 法商拜爾普羅傑特醫藥有限公司 必托里賽（ｐｉｔｏｌｉｓａｎｔ）之新穎調配物及使用方法
CN118806729B (zh) * 2024-06-18 2025-04-22 海南合瑞制药股份有限公司 美沙拉秦肠溶缓释微丸及其制备方法
WO2026003735A1 (en) * 2024-06-28 2026-01-02 Università Degli Studi Di Milano Oral platform for site-specific release to the colon
EP4674409A1 (en) * 2024-07-04 2026-01-07 Roquette Freres Oral tablets for the colonic delivery of therapeutic proteins
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5291419A (en) * 1976-01-28 1977-08-01 Fuji Yakuhin Kogyo Kk Coloring image forming photosensitive sheet
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
DE4217920C2 (de) * 1992-05-30 1996-05-09 Goldwell Gmbh Verfahren zur Herstellung von pulverförmigen Mitteln zum Blondieren von menschlichen Haaren
EP0667148B1 (en) * 1992-11-06 2002-07-03 Hisamitsu Pharmaceutical Co., Inc. Peroral pharmaceutical preparation releasable in lower digestive tract
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
FR2711525B1 (fr) 1993-10-29 1996-01-12 Virbac Laboratoires Forme Galénique à administration orale pour animaux, son procédé de préparation et ses applications.
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
CN1239425A (zh) * 1996-11-15 1999-12-22 普罗克特和甘保尔公司 供结肠释放的具有多层肠溶聚合物包衣的药剂
CA2236605A1 (en) * 1997-05-09 1998-11-09 Yves Duccini Scale inhibitors
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
DE69907479T2 (de) * 1999-12-16 2004-04-08 Laboratorio Medinfar-Produtos Farmacéuticos, S. A. Piroxicam enthaltende gastrointestinale Zubereitung aus merheren Einheiten bestehend
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
FI20000780A7 (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
US6939920B2 (en) 2001-01-08 2005-09-06 The Goodyear Tire & Rubber Company Tire sidewall compounds having improved flex fatigue and tread compound having improved tear strength
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
WO2002096405A1 (en) 2001-05-25 2002-12-05 Ssp Co., Ltd. Drug preparations
US7183321B2 (en) 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
JP2006515318A (ja) * 2002-10-29 2006-05-25 ファルマシア・コーポレーション 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
AU2002361495A1 (en) 2002-12-24 2004-07-22 Lupin Limited Enteric coated fluoxetine composition
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US20050214371A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
WO2007034503A2 (en) 2005-06-20 2007-03-29 Cadila Healthcare Limited Controlled release dosage formulation of duloxetine
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
JP4984695B2 (ja) 2006-07-11 2012-07-25 株式会社明電舎 色素増感型太陽電池及びその製造方法
SK287622B6 (sk) * 2006-07-25 2011-04-05 Peter Pap Odkladacia schránka
WO2008020286A2 (en) 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
EP2079448A2 (en) * 2006-10-10 2009-07-22 Dexcel Pharma Technologies Ltd. Improved release of statins in the intestine
WO2008068584A2 (en) * 2006-12-05 2008-06-12 University Of Witwatersrand, Johannesburg A heterogeneously configured multiparticulate gastrointestinal drug delivery system
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
JP2008214249A (ja) 2007-03-02 2008-09-18 Takeda Chem Ind Ltd 製剤における溶出改善方法および溶出性の改善された製剤
WO2008117814A1 (ja) * 2007-03-26 2008-10-02 Teikoku Seiyaku Co., Ltd. 大腸送達用経口製剤
PT2152250T (pt) * 2007-05-07 2019-12-12 Evonik Operations Gmbh Formas farmacêuticas sólidas que compreendem um revestimento entérico com libertação acelerada do fármaco
US20090162434A1 (en) 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
US20110177164A1 (en) * 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
WO2010147994A1 (en) 2009-06-15 2010-12-23 Amarin Pharma, Inc. Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
CN102548544B (zh) * 2009-10-09 2015-01-21 永进药品工业株式会社 同时具有速效特性和长效特性的药物组合物
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
WO2012075015A2 (en) 2010-11-29 2012-06-07 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
JP2014529630A (ja) 2011-09-07 2014-11-13 ザウラー−ブロシュ、ローラント 哺乳類の消化管における一つあるいは複数の物質の放出制御製剤
CN102319218B (zh) 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
ES2655622T3 (es) 2012-04-30 2018-02-20 Tillotts Pharma Ag Una formulación de fármaco de liberación retardada
US9844436B2 (en) 2012-10-26 2017-12-19 Edwards Lifesciences Corporation Aortic valve and conduit graft implant tool
NZ717159A (en) * 2013-10-29 2019-06-28 Tillotts Pharma Ag A delayed release drug formulation

Also Published As

Publication number Publication date
EP2844220B1 (en) 2019-01-23
AU2013255913B2 (en) 2017-08-31
WO2013164316A1 (en) 2013-11-07
HRP20180965T1 (hr) 2018-08-10
SG11201406798WA (en) 2014-11-27
CU24304B1 (es) 2018-01-10
EP3187171A1 (en) 2017-07-05
ME03364B (me) 2019-10-20
CY1120492T1 (el) 2019-07-10
HUE043238T2 (hu) 2019-08-28
AU2013255914B2 (en) 2017-08-31
NZ629262A (en) 2017-01-27
TW201343202A (zh) 2013-11-01
ES2987408T3 (es) 2024-11-14
CA3052460C (en) 2022-06-07
JOP20200145A1 (ar) 2022-10-30
CN110237056B (zh) 2022-03-08
SI2844220T1 (sl) 2019-05-31
US20150132380A1 (en) 2015-05-14
EA201491781A1 (ru) 2014-12-30
GEP201706759B (en) 2017-10-25
JOP20200146A1 (ar) 2022-10-30
KR102102198B1 (ko) 2020-04-21
AU2017210577A1 (en) 2017-08-24
MX373249B (es) 2020-05-12
TW202037370A (zh) 2020-10-16
CN110200949A (zh) 2019-09-06
US10226430B2 (en) 2019-03-12
EP2844220A1 (en) 2015-03-11
AU2013255913A1 (en) 2014-11-13
US20140056980A1 (en) 2014-02-27
KR102104070B1 (ko) 2020-04-24
DK3189830T3 (en) 2018-07-16
HUE042833T2 (hu) 2019-07-29
RS58625B1 (sr) 2019-05-31
SI3278792T1 (sl) 2019-06-28
PE20142442A1 (es) 2015-01-28
SG11201406799XA (en) 2014-11-27
RS57431B1 (sr) 2018-09-28
LT3278792T (lt) 2019-05-10
TWI700102B (zh) 2020-08-01
JP2015515964A (ja) 2015-06-04
LT2659881T (lt) 2018-02-12
TWI705833B (zh) 2020-10-01
US20150125525A1 (en) 2015-05-07
PT2844220T (pt) 2019-03-27
PH12014502339A1 (en) 2014-12-22
GEP201706736B (en) 2017-09-25
MY190392A (en) 2022-04-20
PH12014502340A1 (en) 2014-12-22
EP2659881B1 (en) 2017-11-29
HRP20180068T1 (hr) 2018-03-23
EA032811B1 (ru) 2019-07-31
RS56839B1 (sr) 2018-04-30
US10272048B2 (en) 2019-04-30
BR122019022551B1 (pt) 2022-07-19
KR20200073296A (ko) 2020-06-23
KR20190127984A (ko) 2019-11-13
JOP20200148B1 (ar) 2023-09-17
US9814681B2 (en) 2017-11-14
TN2014000441A1 (en) 2016-03-30
PT2659881T (pt) 2018-01-29
JOP20200145B1 (ar) 2023-09-17
HUE036187T2 (hu) 2018-06-28
AR090898A1 (es) 2014-12-17
PL2659881T3 (pl) 2018-05-30
DK2844220T3 (en) 2019-04-08
CA2871016C (en) 2023-03-21
CA3080035A1 (en) 2013-11-07
HUE037702T2 (hu) 2018-09-28
TN2014000442A1 (en) 2016-03-30
JOP20200144A1 (ar) 2017-06-16
MX366677B (es) 2019-07-19
SMT202000014T1 (it) 2020-03-13
US11517534B2 (en) 2022-12-06
US20200214987A1 (en) 2020-07-09
KR20190127986A (ko) 2019-11-13
AU2017210571A1 (en) 2017-08-24
SI2844222T1 (sl) 2020-02-28
DK2659881T3 (en) 2018-02-05
HUE046628T2 (hu) 2020-03-30
LT2844220T (lt) 2019-04-10
CU20140123A7 (es) 2015-02-26
CN104271113A (zh) 2015-01-07
MX362529B (es) 2019-01-23
EP3189830B1 (en) 2018-05-23
AU2013255914A1 (en) 2014-11-13
AU2017210577B2 (en) 2018-11-29
US11534406B2 (en) 2022-12-27
ES2673931T3 (es) 2018-06-26
EP3278792A1 (en) 2018-02-07
UY34772A (es) 2013-11-29
CL2014002795A1 (es) 2015-02-13
GEP201706758B (en) 2017-10-25
US9364440B2 (en) 2016-06-14
PH12014502340B1 (en) 2014-12-22
SA113340508B1 (ar) 2016-02-07
SI2659881T1 (en) 2018-03-30
JO3574B1 (ar) 2020-07-05
RS59697B1 (sr) 2020-01-31
KR20200075024A (ko) 2020-06-25
PL3278792T3 (pl) 2019-09-30
CA2871017A1 (en) 2013-11-07
PL2844222T3 (pl) 2020-03-31
JOP20200147B1 (ar) 2023-09-17
EA032514B1 (ru) 2019-06-28
RS58735B1 (sr) 2019-06-28
PT3189830T (pt) 2018-10-19
TW201720430A (zh) 2017-06-16
LT2844222T (lt) 2019-12-27
SI3189830T1 (en) 2018-08-31
TR201905226T4 (tr) 2019-05-21
MX2014012887A (es) 2015-05-08
EP2844222A1 (en) 2015-03-11
ES2714448T3 (es) 2019-05-28
LT3189830T (lt) 2018-07-10
CO7141433A2 (es) 2014-12-12
CN104302274A (zh) 2015-01-21
SMT201900252T1 (it) 2019-07-11
EP3189830A1 (en) 2017-07-12
NZ629260A (en) 2017-01-27
BR112014026933A2 (pt) 2017-06-27
TR201809416T4 (tr) 2018-07-23
EP2844222B1 (en) 2019-11-13
EP3278792B1 (en) 2019-02-20
PE20150129A1 (es) 2015-02-13
BR112014026933B1 (pt) 2022-07-19
KR102198621B1 (ko) 2021-01-06
PL2844220T3 (pl) 2019-06-28
JP2015515965A (ja) 2015-06-04
DK3278792T3 (da) 2019-05-06
SMT201900215T1 (it) 2019-05-10
ME03641B (me) 2020-07-20
CL2014002796A1 (es) 2015-02-06
CA2871016A1 (en) 2013-11-07
ES2720258T3 (es) 2019-07-19
EA201491783A1 (ru) 2014-12-30
CN106983735A (zh) 2017-07-28
EP3187171B1 (en) 2024-09-25
PH12014502339B1 (en) 2014-12-22
PT3278792T (pt) 2019-05-23
JOP20200146B1 (ar) 2023-09-17
JOP20200147A1 (ar) 2022-10-30
AU2017210571B2 (en) 2018-11-29
JP6621662B2 (ja) 2019-12-18
CY1121609T1 (el) 2020-05-29
US20170266117A1 (en) 2017-09-21
EP3187171C0 (en) 2024-09-25
SMT201800095T1 (it) 2018-03-08
EP2659881A1 (en) 2013-11-06
CN104271113B (zh) 2019-03-22
CR20140485A (es) 2015-01-19
CY1122475T1 (el) 2021-01-27
DK2844222T3 (da) 2019-12-09
NZ725409A (en) 2018-05-25
TR201903569T4 (tr) 2019-04-22
WO2013164315A1 (en) 2013-11-07
PT2844222T (pt) 2019-12-30
NO2659881T3 (es) 2018-04-28
CR20190246A (es) 2019-09-03
CY1120215T1 (el) 2018-12-12
GEP201706753B (en) 2017-10-25
CO7151506A2 (es) 2014-12-29
JP6621661B2 (ja) 2019-12-18
JOP20200148A1 (ar) 2022-10-30
US20170035698A1 (en) 2017-02-09
ES2655622T3 (es) 2018-02-20
CN110200949B (zh) 2021-11-16
CA3052460A1 (en) 2013-11-07
MY169161A (en) 2019-02-19
SMT201800360T1 (it) 2018-09-13
PL3189830T3 (pl) 2018-11-30
PE20190625A1 (es) 2019-04-26
MX2014012888A (es) 2015-04-13
MY169088A (en) 2019-02-15
CN110237056A (zh) 2019-09-17
TWI618547B (zh) 2018-03-21
SA115370043B1 (ar) 2016-05-24
KR20150004910A (ko) 2015-01-13
CR20190245A (es) 2019-07-29
KR20150004911A (ko) 2015-01-13
KR102177773B1 (ko) 2020-11-12
ES2761341T3 (es) 2020-05-19
CR20140486A (es) 2015-01-19
BR112014026935A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
JOP20200148B1 (ar) تركيبة عقار ذو إطلاق متأخر
NZ717159A (en) A delayed release drug formulation
PH12018501311A1 (en) A delayed release drug formulation
TH148827A (th) สูตรผสมยาชนิดปลดปล่อยแบบชะลอ
CU24302B1 (es) Formulación de fármaco de liberación retardada